🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/08/2016 | 97,31 | 98,98 | 96,85 | 98,20 | +1,24% | 2,19% | 1.988.600 |
| 29/07/2016 | 96,28 | 97,07 | 95,41 | 97,00 | +0,82% | 1,72% | 1.012.800 |
| 28/07/2016 | 95,35 | 98,50 | 95,08 | 96,21 | +0,21% | 3,59% | 1.455.300 |
| 27/07/2016 | 94,65 | 97,06 | 94,65 | 96,01 | +1,08% | 2,55% | 2.299.200 |
| 26/07/2016 | 95,90 | 95,91 | 93,87 | 94,98 | -0,82% | 2,13% | 1.657.900 |
| 25/07/2016 | 93,51 | 96,52 | 93,46 | 95,77 | +2,00% | 3,27% | 1.912.000 |
| 22/07/2016 | 93,63 | 94,29 | 92,70 | 93,89 | +0,73% | 1,70% | 1.235.500 |
| 21/07/2016 | 91,34 | 93,61 | 91,00 | 93,21 | +2,26% | 2,86% | 1.783.300 |
| 20/07/2016 | 87,30 | 91,22 | 86,53 | 91,15 | +4,25% | 5,37% | 1.309.400 |
| 19/07/2016 | 89,08 | 89,72 | 86,64 | 87,43 | -2,23% | 3,46% | 1.112.300 |
| 18/07/2016 | 90,06 | 90,80 | 89,32 | 89,42 | -0,88% | 1,64% | 1.127.200 |
| 15/07/2016 | 89,34 | 90,86 | 88,05 | 90,21 | +2,34% | 3,15% | 1.309.200 |
| 14/07/2016 | 88,98 | 89,08 | 87,50 | 88,15 | +0,42% | 1,78% | 990.200 |
| 13/07/2016 | 90,32 | 90,41 | 87,70 | 87,78 | -2,06% | 3,00% | 945.700 |
| 12/07/2016 | 91,10 | 91,45 | 89,14 | 89,63 | -0,52% | 2,54% | 1.547.000 |
| 11/07/2016 | 90,09 | 90,82 | 89,27 | 90,10 | +1,28% | 1,72% | 1.388.200 |
| 08/07/2016 | 90,08 | 90,43 | 88,65 | 88,96 | -1,21% | 1,98% | 1.794.300 |
| 07/07/2016 | 89,69 | 90,83 | 89,00 | 90,05 | +0,43% | 2,04% | 1.254.000 |
| 06/07/2016 | 86,16 | 89,90 | 85,92 | 89,66 | +3,64% | 4,62% | 1.705.300 |
| 05/07/2016 | 87,11 | 87,33 | 85,53 | 86,51 | -1,40% | 2,07% | 870.100 |
| 01/07/2016 | 85,67 | 88,46 | 85,17 | 87,74 | +2,00% | 3,84% | 1.292.700 |
| 30/06/2016 | 85,23 | 86,64 | 84,08 | 86,02 | +1,20% | 3,00% | 1.418.500 |
| 29/06/2016 | 83,85 | 85,94 | 82,69 | 85,00 | +1,87% | 3,88% | 1.754.300 |
| 28/06/2016 | 80,54 | 83,55 | 80,54 | 83,44 | +4,51% | 3,74% | 1.536.400 |
| 27/06/2016 | 81,17 | 82,09 | 79,59 | 79,84 | -2,52% | 3,08% | 1.906.000 |
| 24/06/2016 | 83,58 | 85,79 | 81,82 | 81,90 | -7,14% | 4,75% | 2.298.500 |
| 23/06/2016 | 86,21 | 88,28 | 85,04 | 88,20 | +3,50% | 3,76% | 1.398.000 |
| 22/06/2016 | 85,20 | 89,17 | 85,09 | 85,22 | -0,07% | 4,79% | 1.917.800 |
| 21/06/2016 | 86,80 | 87,64 | 83,50 | 85,28 | -1,66% | 4,77% | 1.881.900 |
| 20/06/2016 | 87,74 | 89,01 | 86,52 | 86,72 | -0,01% | 2,84% | 1.272.900 |